Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, the FDA issued a warning letter to Infinite Product Company LLLP (doing business as Infinite CBD) on November 22, 2019, regarding products classified as drugs. Without access to the full letter text or detailed subject information, the specific violations cannot be determined, though the warning likely concerns marketing claims, product composition, manufacturing practices, or regulatory compliance issues common to CBD product enforcement. The letter was issued under the FDA's drug regulatory authority, indicating the agency determined these products were being marketed or formulated in a manner inconsistent with drug regulations.